A Randomized, Open-label, Phase 3 Study of Setidegrasib (ASP3082) versus Docetaxel in Participants with KRAS G12D-mutated Locally Advanced (Unresectable) or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on or After Platinum-based Chemotherapy and Checkpoint Inhibitor Therapy (CPI)
This Phase 3 study looks at a new treatment called setidegrasib (ASP3082) for adults with advanced non-small cell lung cancer. The study is specifically for patients whose tumours have a genetic fault known as a KRAS G12D mutation, and whose cancer has continued to grow after previous chemotherapy and immunotherapy. Currently, the usual next treatment option is a chemotherapy drug called docetaxel. In this trial, researchers want to see if the new medicine, setidegrasib, works better than docetaxel at slowing down cancer growth and helping people live longer. Participants will be placed into one of two treatment groups by chance. Doctors will monitor how well the treatment works using regular scans, check for any side effects, and ask participants questions about their everyday symptoms, such as coughing and shortness of breath, to see how the treatments affect overall quality of life.
At a glance
What is this study about?
Non-small cell lung cancer is the most common type of lung cancer. In some people, the cancer cells carry specific changes in their genes that cause the cells to grow out of control. One of these changes is called a KRAS G12D mutation. While standard treatments like chemotherapy and immunotherapy can work well at first, the cancer can eventually find ways around them and start growing again.
When standard treatments stop working, doctors usually offer a chemotherapy drug called docetaxel. While docetaxel can help manage the disease, doctors are searching for newer, more targeted treatments that can work better and cause fewer unwanted effects. Setidegrasib is a new medicine designed specifically to target and turn off the faulty KRAS G12D signal inside the cancer cells.
This trial is a Phase 3 study, which means the new medicine is being compared directly against the current standard treatment to see which is better. Researchers will measure how long patients live without their cancer getting worse, how long they live overall, and whether the new drug helps shrink tumours.
Taking part in this research also helps doctors understand how these treatments affect daily life. Participants will be asked about common lung cancer symptoms, like cough, chest pain, and breathlessness, to see if the treatment improves day-to-day comfort and wellbeing.
Key takeaways
- The trial compares a new targeted drug (setidegrasib) with standard chemotherapy (docetaxel).
- It is for adults with advanced non-small cell lung cancer with a KRAS G12D mutation.
- Participants must have already tried platinum chemotherapy and immunotherapy.
- Treatment is decided by random assignment and given via a drip in hospital.
- Taking part is completely voluntary, and you can withdraw at any point.
Who may be eligible?
This trial is for adults aged 18 and over who have advanced or metastatic non-small cell lung cancer. Advanced means the cancer cannot be removed with surgery, and metastatic means it has spread to other parts of the body.
To be considered, your tumour must test positive for a specific gene change called the KRAS G12D mutation. Your doctor or hospital team can find this out by testing a small sample of your tumour tissue or through blood tests.
You must also have already received two key types of cancer treatment: a platinum-based chemotherapy and an immunotherapy drug. If your cancer has grown or come back during or after these treatments, you may be eligible. You will also need to be well enough to carry out daily activities and have satisfactory blood test and organ function results.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with advanced or metastatic non-small cell lung cancer.
- My cancer has been confirmed to have the KRAS G12D gene change.
- My cancer has progressed after receiving platinum chemotherapy and immunotherapy.
- I am well enough to attend regular hospital appointments for tests and treatment.
What does participation involve?
If you join the trial, you will be assigned by a computer to receive either setidegrasib or docetaxel. You cannot choose your group, and your doctor cannot choose for you. Both treatments are given at the hospital through a drip into a vein (an intravenous infusion).
Before starting, you will have health checks including blood tests, heart traces (ECGs), and imaging scans (such as CT or MRI scans). During the study, you will visit the hospital regularly to receive your medicine, have safety check-ups, and get repeat scans every few weeks to check your tumour. You will also be asked to fill in simple questionnaires about your symptoms and daily energy levels.
You will continue to receive the trial treatment for as long as it is helping you and the side effects are manageable. If you stop the treatment, the study team will still stay in touch periodically to check on your health.
Potential risks and benefits
Locations (6)
- —UnverifiedItaly
- —UnverifiedPoland
- —UnverifiedSpain
- —UnverifiedFrance
- —UnverifiedBelgium
- —UnverifiedGermany
Common questions
What is a KRAS G12D mutation?
It is a specific, faulty switch inside cancer cells that tells them to grow and divide. Testing your tumour tissue can show whether your cancer has this specific change.
Can I choose which medicine I receive?
No. A computer puts you into a treatment group at random. This process gives both groups a fair comparison and ensures the trial results are reliable.
Will I have to pay for the trial treatment?
No. The trial medication, extra tests, and hospital study visits are provided free of charge.
How often will I need to visit the hospital?
You will need to visit the clinic regularly for infusions, blood tests, and scans. The study team will give you a full schedule before you decide to join.
What happens if my cancer gets worse during the trial?
If scans show that the treatment is no longer working, your doctor will discuss stopping the trial medicine and help you choose the best next treatment option.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.